
Kevin P. Kerns
Examiner (ID: 172, Phone: (571)272-1178 , Office: P/1735 )
| Most Active Art Unit | 1735 |
| Art Unit(s) | 1725, 1722, 1793, 1735 |
| Total Applications | 2439 |
| Issued Applications | 1772 |
| Pending Applications | 153 |
| Abandoned Applications | 538 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 13551911
[patent_doc_number] => 20180327503
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-11-15
[patent_title] => ANTAGONIST ANTI-IL-7 RECEPTOR ANTIBODIES AND METHODS
[patent_app_type] => utility
[patent_app_number] => 16/040945
[patent_app_country] => US
[patent_app_date] => 2018-07-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33061
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16040945
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/040945 | ANTAGONIST ANTI-IL-7 RECEPTOR ANTIBODIES AND METHODS | Jul 19, 2018 | Abandoned |
Array
(
[id] => 16224125
[patent_doc_number] => 20200249242
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-06
[patent_title] => BIOMARKER COMBINATIONS TO SIMULTANEOUSLY EVALUATE NON-ALCOHOLIC STEATOHEPATITIS AND HEPATIC FIBROSIS STATUS
[patent_app_type] => utility
[patent_app_number] => 16/632404
[patent_app_country] => US
[patent_app_date] => 2018-07-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16601
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16632404
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/632404 | Biomarker combinations to simultaneously evaluate non-alcoholic steatohepatitis and hepatic fibrosis status | Jul 18, 2018 | Issued |
Array
(
[id] => 15245257
[patent_doc_number] => 10508141
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-12-17
[patent_title] => Nucleic acids encoding HLA-A24 agonist epitopes of MUC1-C oncoprotein
[patent_app_type] => utility
[patent_app_number] => 16/034654
[patent_app_country] => US
[patent_app_date] => 2018-07-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25065
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16034654
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/034654 | Nucleic acids encoding HLA-A24 agonist epitopes of MUC1-C oncoprotein | Jul 12, 2018 | Issued |
Array
(
[id] => 17937058
[patent_doc_number] => 11471490
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-18
[patent_title] => T cells surface-loaded with immunostimulatory fusion molecules and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/628342
[patent_app_country] => US
[patent_app_date] => 2018-07-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 71
[patent_figures_cnt] => 98
[patent_no_of_words] => 69512
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 115
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16628342
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/628342 | T cells surface-loaded with immunostimulatory fusion molecules and uses thereof | Jul 2, 2018 | Issued |
Array
(
[id] => 14406893
[patent_doc_number] => 20190169290
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-06-06
[patent_title] => COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE
[patent_app_type] => utility
[patent_app_number] => 16/023682
[patent_app_country] => US
[patent_app_date] => 2018-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33974
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16023682
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/023682 | COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE | Jun 28, 2018 | Abandoned |
Array
(
[id] => 16008977
[patent_doc_number] => 20200179331
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-11
[patent_title] => Peptide-Artesunate Conjugates as Targeted Anti-Cancer Agents
[patent_app_type] => utility
[patent_app_number] => 16/627239
[patent_app_country] => US
[patent_app_date] => 2018-06-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9764
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16627239
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/627239 | Peptide-Artesunate Conjugates as Targeted Anti-Cancer Agents | Jun 28, 2018 | Abandoned |
Array
(
[id] => 17741462
[patent_doc_number] => 11389507
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-07-19
[patent_title] => Use of interleukin-4-inducing principle of
[patent_app_type] => utility
[patent_app_number] => 16/623230
[patent_app_country] => US
[patent_app_date] => 2018-06-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 6710
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16623230
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/623230 | Use of interleukin-4-inducing principle of | Jun 13, 2018 | Issued |
Array
(
[id] => 17860912
[patent_doc_number] => 11442068
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-13
[patent_title] => Method for diagnosing and treating fibromyalgia
[patent_app_type] => utility
[patent_app_number] => 16/002689
[patent_app_country] => US
[patent_app_date] => 2018-06-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 7020
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 201
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16002689
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/002689 | Method for diagnosing and treating fibromyalgia | Jun 6, 2018 | Issued |
Array
(
[id] => 14280425
[patent_doc_number] => 20190137497
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-05-09
[patent_title] => SYSTEMS AND COMPOSITIONS FOR DIAGNOSING BARRETT'S ESOPHAGUS AND METHODS OF USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 16/002098
[patent_app_country] => US
[patent_app_date] => 2018-06-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31444
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16002098
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/002098 | Systems and compositions for diagnosing Barrett's esophagus and methods of using the same | Jun 6, 2018 | Issued |
Array
(
[id] => 13444107
[patent_doc_number] => 20180273596
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-09-27
[patent_title] => MODIFIED INTERLEUKIN-7 PROTEIN AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/000049
[patent_app_country] => US
[patent_app_date] => 2018-06-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10098
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16000049
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/000049 | Modified interleukin-7 protein | Jun 4, 2018 | Issued |
Array
(
[id] => 13586523
[patent_doc_number] => 20180344810
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-12-06
[patent_title] => IL-2RBETA-SELECTIVE AGONISTS IN COMBINATION WITH AN ANTI-CTLA-4 ANTIBODY OR AN ANTI-PD-1 ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 15/997487
[patent_app_country] => US
[patent_app_date] => 2018-06-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11313
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 57
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15997487
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/997487 | Il-2Rb-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody | Jun 3, 2018 | Issued |
Array
(
[id] => 17089781
[patent_doc_number] => 11117958
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-09-14
[patent_title] => Anti-human interleukin-2 antibodies and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/616172
[patent_app_country] => US
[patent_app_date] => 2018-05-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 10
[patent_no_of_words] => 10640
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 124
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16616172
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/616172 | Anti-human interleukin-2 antibodies and uses thereof | May 24, 2018 | Issued |
Array
(
[id] => 16800223
[patent_doc_number] => 10995144
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-05-04
[patent_title] => Methods of detecting a solid tumor with anti-IL1RAP antibodies
[patent_app_type] => utility
[patent_app_number] => 15/988674
[patent_app_country] => US
[patent_app_date] => 2018-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 23
[patent_no_of_words] => 14034
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 105
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15988674
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/988674 | Methods of detecting a solid tumor with anti-IL1RAP antibodies | May 23, 2018 | Issued |
Array
(
[id] => 13182203
[patent_doc_number] => 10106603
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-10-23
[patent_title] => Treatment of fibrosis
[patent_app_type] => utility
[patent_app_number] => 15/988463
[patent_app_country] => US
[patent_app_date] => 2018-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 66
[patent_figures_cnt] => 106
[patent_no_of_words] => 33270
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15988463
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/988463 | Treatment of fibrosis | May 23, 2018 | Issued |
Array
(
[id] => 18589177
[patent_doc_number] => 11738049
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-08-29
[patent_title] => Kinase mutants and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/615032
[patent_app_country] => US
[patent_app_date] => 2018-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 15287
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16615032
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/615032 | Kinase mutants and uses thereof | May 23, 2018 | Issued |
Array
(
[id] => 13576931
[patent_doc_number] => 20180340014
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-11-29
[patent_title] => Targeted Immunotolerance
[patent_app_type] => utility
[patent_app_number] => 15/988311
[patent_app_country] => US
[patent_app_date] => 2018-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57576
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15988311
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/988311 | Targeted immunotolerance | May 23, 2018 | Issued |
Array
(
[id] => 15765913
[patent_doc_number] => 20200113974
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-16
[patent_title] => ANTIBODY-CYTOKINE ENGRAFTED PROTEINS AND METHODS OF USE FOR IMMUNE RELATED DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/616138
[patent_app_country] => US
[patent_app_date] => 2018-05-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28949
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -36
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16616138
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/616138 | Antibody-cytokine engrafted proteins and methods of use for immune related disorders | May 21, 2018 | Issued |
Array
(
[id] => 18383430
[patent_doc_number] => 11654194
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-05-23
[patent_title] => PD-L1 antibody pharmaceutical composition and use thereof
[patent_app_type] => utility
[patent_app_number] => 16/614148
[patent_app_country] => US
[patent_app_date] => 2018-05-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 3
[patent_no_of_words] => 11356
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 46
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16614148
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/614148 | PD-L1 antibody pharmaceutical composition and use thereof | May 14, 2018 | Issued |
Array
(
[id] => 14213977
[patent_doc_number] => 20190119373
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-04-25
[patent_title] => ANTIBODY RECOGNIZING HUMAN LEUKEMIA INHIBITORY FACTOR (LIF) AND USE OF ANTI-LIF ANTIBODIES IN THE TREATMENT OF DISEASES ASSOCIATED WITH UNWANTED CELL PROLIFERATION
[patent_app_type] => utility
[patent_app_number] => 15/978362
[patent_app_country] => US
[patent_app_date] => 2018-05-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13711
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15978362
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/978362 | Antibody recognizing human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation | May 13, 2018 | Issued |
Array
(
[id] => 18997126
[patent_doc_number] => 11913962
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-27
[patent_title] => Materials and methods for subjects at risk for viral reactivation
[patent_app_type] => utility
[patent_app_number] => 16/613411
[patent_app_country] => US
[patent_app_date] => 2018-05-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 21
[patent_no_of_words] => 11693
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 252
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16613411
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/613411 | Materials and methods for subjects at risk for viral reactivation | May 13, 2018 | Issued |